Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

TherapeuticsMD begins phase I study of its vaginal estradiol suppository

Aug. 13, 2013

Phase II clinical trial data presented for new monoclonal antibody for type 1 diabetes

Aug. 13, 2013

Bayer Intellectual Property discloses novel GnRH receptor antagonists

Aug. 12, 2013

mRNA-mediated inhibition of transcription improves cardiovascular disease-related etiologies

Aug. 9, 2013

Daiichi Sankyo designs new agents for diabetes and obesity

Aug. 8, 2013

Piramal Enterprises receives IND clearance from FDA for novel DGAT1 inhibitor

Aug. 8, 2013

Ultragenyx commences development program in GLUT-1 deficiency syndrome

Aug. 7, 2013

Novel MetAP 2 inhibitors divulged by Zafgen

Aug. 7, 2013

Antisense Therapeutics provides update on phase II ATL-1103 trial

Aug. 7, 2013

Bayer profiles novel PR modulator for the treatment of uterine fibrosis

Aug. 7, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...